Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand and a significant data breach in 2023. The acquisition excludes Lemonaid Health, which will be shut down. Regeneron pledges to uphold privacy commitments and legal safeguards for the genetic data of 15 million users, with a court-appointed overseer monitoring data use.
Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand and a significant data breach in 2023. The acquisition excludes Lemonaid Health, which will be shut down. Regeneron pledges to uphold privacy commitments and legal safeguards for the genetic data of 15 million users, with a court-appointed overseer monitoring data use.
टिप्पणियाँ
एक टिप्पणी भेजें